Hjem › Rhabdomyosarkom
Rhabdomyosarkom kliniske forsøg rekrutterer i USA
26 studier for Rhabdomyosarkom rekrutterer deltagere på steder over hele USA.
Byer med flest studier
- Houston, TX6 studier
- Memphis, TN6 studier
- Washington, DC5 studier
- Philadelphia, PA4 studier
- Salt Lake City, UT4 studier
- Boston, MA4 studier
- Seattle, WA3 studier
- Aurora, CO3 studier
- Dallas, TX3 studier
- Birmingham, AL3 studier
- The Bronx, NY3 studier
- Baltimore, MD3 studier
Efter delstat
- Alabama3 studier
- Californien7 studier
- Colorado3 studier
- District of Columbia4 studier
- Florida3 studier
- Maryland4 studier
- Massachusetts4 studier
- New York4 studier
- Ohio5 studier
- Pennsylvania5 studier
- Tennessee8 studier
- Texas9 studier
- Utah4 studier
- Washington3 studier
Nyligt opdaterede studier
Officiel studietekst (engelsk)
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
RekruttererFase 1
Alder 3 til 39 · Alle køn · Opdateret 29. sep. 2026 · NCT06865664Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
RekruttererFase 1
24 Months – 18 Years · Alle køn · Opdateret 25. sep. 2026 · NCT06441331Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RekruttererFase 1/2
Op til 30 år · Alle køn · Opdateret 3. sep. 2026 · NCT06541262A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
RekruttererFase 3
Op til 50 år · Alle køn · Opdateret 25. aug. 2026 · NCT07466316Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
Rekrutterer
Alle aldre · Alle køn · Opdateret 21. aug. 2026 · NCT07514819Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RekruttererFase 1
Alder 1 til 23 · Alle køn · Opdateret 13. aug. 2026 · NCT07172958Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 6. aug. 2026 · NCT05210374Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
RekruttererFase 1
Alder 1 til 21 · Alle køn · Opdateret 6. aug. 2026 · NCT04715191Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
RekruttererTidlig fase 1
Alder 18 og opefter · Alle køn · Opdateret 31. jul. 2026 · NCT07628634PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
RekruttererFase 1/2
Alder 1 til 30 · Alle køn · Opdateret 22. jul. 2026 · NCT06721689Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Rekrutterer
Op til 39 år · Alle køn · Opdateret 13. jul. 2026 · NCT06796543Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RekruttererFase 1/2
6 Months – 25 Years · Alle køn · Opdateret 30. jun. 2026 · NCT06625190Familial Investigations of Childhood Cancer Predisposition
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 17. jun. 2026 · NCT03050268Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
RekruttererFase 2
Op til 22 år · Alle køn · Opdateret 15. jun. 2026 · NCT06023641VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
RekruttererFase 1/2
6 Months – 30 Years · Alle køn · Opdateret 2. jun. 2026 · NCT04796012B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RekruttererFase 1
Op til 21 år · Alle køn · Opdateret 19. maj 2026 · NCT04897321Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
RekruttererFase 1/2
12 Months – 30 Years · Alle køn · Opdateret 19. maj 2026 · NCT04901702Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
RekruttererFase 1
Alder 1 til 30 · Alle køn · Opdateret 15. apr. 2026 · NCT04308330Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
RekruttererFase 2
Alder 1 til 50 · Alle køn · Opdateret 13. mar. 2026 · NCT01804634Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
RekruttererFase 1/2
Alder 12 til 49 · Alle køn · Opdateret 19. feb. 2026 · NCT06709495Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
RekruttererFase 1
Alder 1 til 26 · Alle køn · Opdateret 17. feb. 2026 · NCT07148050HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RekruttererFase 1
Alder 1 til 25 · Alle køn · Opdateret 22. jan. 2026 · NCT04995003Molecular Analysis Of Solid Tumors
RekruttererObservationsstudie
Op til 25 år · Alle køn · Opdateret 12. nov. 2025 · NCT01050296Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RekruttererFase 1
Op til 21 år · Alle køn · Opdateret 3. nov. 2025 · NCT06198296Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RekruttererFase 1
7 Months – 21 Years · Alle køn · Opdateret 16. okt. 2025 · NCT02508038Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.